Present Molecular Limitations of ON-Bipolar Cell Targeted Gene Therapy
نویسندگان
چکیده
منابع مشابه
Present Molecular Limitations of ON-Bipolar Cell Targeted Gene Therapy
Recent studies have demonstrated the safety and efficacy of ocular gene therapy based on adeno-associated viral vectors (AAVs). Accordingly, a surge in promising new gene therapies is entering clinical trials, including the first optogenetic therapy for vision restoration. To date, optogenetic therapies for vision restoration target either the retinal ganglion cells (GCs) or presynaptic ON-bipo...
متن کاملPresent Status and Problems on Molecular Targeted Therapy of Cancer
Numerous clinical trials of molecular targeted drugs for cancer have been conducted, with remarkable results for certain drugs and accumulation of "negative data" causing a hitch in the development plan for some other compounds. Five recent issues and problems of molecular targeted therapies were discussed critically. Drug discovery and effects against driver mutations (activating mutations) an...
متن کاملTargeted molecular therapy of GBM.
Major advances in molecular biology, cellular biology and genomics have substantially improved our understanding of cancer. Now, these advances are being translated into therapy. Targeted therapy directed at specific molecular alterations is already creating a shift in the treatment of cancer patients. Glioblastoma (GBM), the most common brain cancer of adults, is highly suited for this new app...
متن کاملHepatotoxicity of molecular targeted therapy
A constant increase in occurrence of neoplasms is observed; hence new methods of therapy are being intensively researched. One of the methods of antineoplastic treatment is molecular targeted therapy, which aims to influence individual processes occurring in cells. Using this type of medications is associated with unwanted effects resulting from the treatment. Liver damage is a major adverse ef...
متن کاملBrain endothelial cell‐targeted gene therapy of neurovascular disorders
Neurovascular disorders are difficult to treat due to the blood–brain barrier (BBB), which prevents delivery of most drugs from the blood into the brain. Gene therapy can potentially overcome this barrier, but classical vectors are neither efficient nor specific enough to provide long-lasting treatment or avoid off-target effects. In this issue of EMBO Molecular Medicine, Körbelin et al (2016) ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Frontiers in Neuroscience
سال: 2017
ISSN: 1662-453X
DOI: 10.3389/fnins.2017.00161